Seasonal Influenza Vaccine Market in Asia-Pacific to 2018:Latest Industry Size Research Report

  • 165 views
Uploaded on

Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New …

Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2018. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
165
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
1
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2018. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented. Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region. GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 9% during the period 2011–2018 from $1,015m in 2011 to $1,879m by 2018. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies. GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 2. market forecast to grow at a healthy growth rate during the period 2011–2018. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts. GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future. Scope The report analyses vaccination patterns, market characterization, regulatory landscape, pipeline analysis, competitive landscape and key M&A trends in the seasonal influenza vaccine market in the APAC region. The report covers Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore. Market forecasts for the seasonal influenza vaccines from 2011 to 2018 Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share. Key drivers and restraints that have created significant impact on the market. Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell. Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2012 in the seasonal influenza vaccine market. Reasons to Buy The report will aid business development and marketing executives strategizing their product launches: Build effective strategies to launch their pipeline products by identifying potential geographies. Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps. Develop key strategic initiatives by studying the key strategies of top competitors. Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth. Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety. table Of Contents 1 Table Of Contents 1.1 List Of Figures 1.2 List Of Tables 2 Executive Summary 2.1 Seasonal Influenza Vaccine Market In Asia-pacific Is Set To Grow At A Cagr Of 8.9% During The 2011–2018 Forecast Period 2.2 Government Efforts In Asia-pacific Are Driving The Seasonal Influenza Vaccine Market Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 3. 2.3 Novel Vaccines And New Production Technologies Will Revolutionize The Seasonal Influenza Vaccines Market 3 Seasonal Influenza Vaccine Market In Asia-pacific – Introduction 3.1 Gbi Research Report Guidance 4 Seasonal Influenza Vaccine Market In Asia-pacific – Market Overview 4.1 Market Characterization And Forecasts 4.2 Revenue By Geographical Segmentation 5 Seasonal Influenza Vaccine Market In Asia-pacific – Australia 5.1 Registration Process And Regulations 5.2 Market Characterization And Forecasts 5.3 Cost Of Vaccination 5.4 Vaccination Pattern 5.4.1 Population 5.4.2 Vaccinated Population Contribution 5.4.3 Vaccination Coverage 5.4.4 Number Of Doses Per Person 5.4.5 Total Number Of Doses 5.4.6 Dose Contribution 5.5 Drivers And Barriers 5.5.1 Drivers 5.5.1.1 Government Support For Immunization Against Seasonal Influenza 5.5.2 Restraints 5.5.2.1 Seasonal Influenza Vaccines Kept Out Of Pharmaceutical Benefits Scheme 5.5.2.2 Incidences Of Adverse Reactions After Vaccination 6 Seasonal Influenza Vaccine Market In Asia-pacific – China 6.1 Registration Process And Regulations 6.2 Market Characterization And Forecasts 6.3 Cost Of Vaccination 6.4 Vaccination Pattern 6.4.1 Population 6.4.2 Vaccinated Population Contribution 6.4.3 Vaccination Coverage 6.4.4 Number Of Doses Per Person 6.4.5 Total Number Of Doses 6.4.6 Dose Contribution Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 4. 6.5 Competitive Landscape 6.6 Drivers And Barriers 6.6.1 Drivers 6.6.1.1 High Awareness Due To Pandemic Influenza 6.6.1.2 Availability Of Low-cost Flu Vaccines 6.6.2 Barriers 6.6.2.1 Absence Of A National Influenza Vaccination Program 6.6.2.2 Lack Of Manufacturing Capacity 7 Seasonal Influenza Vaccine Market In Asia-pacific – Hong Kong 7.1 Registration Process And Regulations 7.2 Market Characterization And Forecasts 7.3 Cost Of Vaccination 7.4 Vaccination Pattern 7.4.1 Population 7.4.2 Vaccinated Population Contribution 7.4.3 Vaccination Coverage 7.4.4 Number Of Doses Per Person 7.4.5 Total Number Of Doses 7.4.6 Dose Contribution 7.5 Competitive Landscape 7.6 Drivers And Barriers 7.6.1 Drivers 7.6.1.1 Low Price Of Seasonal Influenza Vaccine 7.6.1.2 Government Programs For Seasonal Influenza Vaccination 7.6.2 Restraints 7.6.2.1 Low Government Contribution 8 Seasonal Influenza Vaccine Market In Asia-pacific – India 8.1 Registration Process And Regulations 8.2 Market Characterization And Forecasts 8.3 Cost Of Vaccination 8.4 Drivers And Barriers 8.4.1 Drivers 8.4.1.1 Increasing Awareness Of Seasonal Influenza 8.4.1.2 Low-cost Vaccine Expected To Be Available In The Future 8.4.2 Barriers 8.4.2.1 Low Vaccination Coverage For Seasonal Influenza 8.4.2.2 Absence Of A National Influenza Vaccination Program 8.4.2.3 Absence Of Low-cost Domestic Manufacturers Of Seasonal Influenza Vaccines In India Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 5. 9 Seasonal Influenza Vaccine Market In Asia-pacific – Japan 9.1 Registration Process And Regulations 9.2 Market Characterization And Forecasts 9.3 Cost Of Vaccination 9.4 Vaccinated Population 9.4.1 Population 9.4.2 Vaccinated Population Contribution 9.4.3 Vaccination Coverage 9.4.3.1 Number Of Doses Per Person 9.4.3.2 Total Number Of Doses 9.5 Drivers And Restraints 9.5.1 Drivers 9.5.1.1 Influenza Immunization Program 9.5.1.2 Incidences Of Pandemic Influenza 9.5.1.3 Rapidly Growing Elderly Population 9.5.1.4 Subsidized Immunization For The Elderly 9.5.2 Barriers 9.5.2.1 Non-reimbursement Of Influenza Vaccination Costs 9.5.2.2 Limited Availability Period For Subsidized Vaccines 9.5.2.3 Lack Of Scientific Studies Establishing Safety And Efficacy Of Flu Vaccines In Japan 9.5.2.4 High Vaccine Cost 10 Seasonal Influenza Vaccine Market In Asia-pacific – Malaysia 10.1 Registration Process And Regulations 10.2 Market Characterization And Forecasts 10.3 Cost Of Vaccination 10.4 Vaccination Pattern 10.4.1 Population 10.4.2 Vaccinated Population Contribution 10.4.3 Vaccination Coverage 10.4.4 Number Of Doses Per Person 10.4.5 Total Number Of Doses 10.4.6 Dose Contribution 10.5 Competitive Landscape 10.6 Drivers And Barriers 10.6.1 Drivers 10.6.1.1 Rapidly Increasing Vaccination Coverage 10.6.2 Barriers 10.6.2.1 Low Government Contribution 10.6.2.2 Low Overall Coverage 10.6.2.3 High Price Of Vaccine Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 6. 11 Seasonal Influenza Vaccine Market In Asia-pacific – New Zealand 11.1 Registration Process And Regulations 11.2 Market Characterization And Forecasts 11.3 Cost Of Vaccination 11.4 Vaccination Pattern 11.4.1 Population 11.4.2 Vaccinated Population Contribution 11.4.3 Vaccination Coverage 11.4.4 Number Of Doses Per Person 11.4.5 Total Number Of Doses 11.4.6 Dose Contribution 11.5 Competitive Landscape 11.6 Drivers And Barriers 11.6.1 Drivers 11.6.1.1 Increasing Vaccination Coverage 11.6.1.2 Government Support For Immunization 11.6.1.3 Low Vaccine Price 11.6.2 Barriers 11.6.2.1 Low Vaccination Coverage For Influenza In Children 12 Seasonal Influenza Vaccine Market In Asia-pacific – Philippines 12.1 Registration Process And Regulations 12.2 Market Characterization And Forecasts 12.3 Cost Of Vaccination 12.4 Vaccination Pattern 12.4.1 Population 12.4.2 Vaccinated Population Contribution 12.4.3 Vaccination Coverage 12.4.4 Number Of Doses Per Person 12.4.5 Total Number Of Doses 12.4.6 Dose Contribution 12.5 Competitive Landscape 12.6 Drivers And Barriers 12.6.1 Drivers 12.6.1.1 Population Growth 12.6.1.2 Rapid Increase In Vaccination Coverage 12.6.2 Restraints 12.6.2.1 Low Government Contribution 12.6.2.2 High Price Of Vaccine 13 Seasonal Influenza Vaccine Market In Asia-pacific – Singapore Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 7. 13.1 Registration Process And Regulations 13.2 Market Characterization And Forecasts 13.3 Cost Of Vaccination 13.4 Vaccination Pattern 13.4.1 Population 13.4.2 Vaccinated Population Contribution 13.4.3 Vaccination Coverage 13.4.4 Number Of Doses Per Person 13.4.5 Total Number Of Doses 13.4.6 Dose Contribution 13.5 Competitive Landscape 13.6 Drivers And Barriers 13.6.1 Drivers 13.6.1.1 Rapidly Increasing Vaccination Coverage 13.6.1.2 Increase In Elderly Population 13.6.2 Barriers 13.6.2.1 Low Government Contribution 14 Seasonal Influenza Vaccine Market In Asia-pacific – Taiwan 14.1 Registration Process And Regulations 14.2 Market Characterization And Forecasts 14.3 Cost Of Vaccination 14.4 Vaccination Pattern 14.4.1 Population 14.4.2 Vaccinated Population Contribution 14.4.3 Vaccination Coverage 14.4.4 Number Of Doses Per Person 14.4.5 Total Number Of Doses 14.4.6 Dose Contribution 14.5 Competitive Landscape 14.6 Drivers And Barriers 14.6.1 Drivers 14.6.1.1 Growth In Elderly Population 14.6.1.2 Government Support For Immunization 14.6.1.3 Low Price Of Vaccine 14.6.2 Restraints 14.6.2.1 Stagnating Vaccination Coverage 15 Seasonal Influenza Vaccine Market In Asia-pacific - Pipeline Analysis 15.1 Pipeline Analysis By Phase 15.2 Product Profiles Of Promising Molecules Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 8. 15.2.1 Optaflu 15.2.1.1 Overview 15.2.1.2 Efficacy 15.2.1.3 Safety 15.2.1.4 Clinical Study Details 15.2.2 Gsk2186877a 15.2.2.1 Overview 15.2.2.2 Efficacy 15.2.2.3 Safety 15.2.2.4 Clinical Study Details 15.2.3 Intanza/flu-id 15.2.3.1 Overview 15.2.3.2 Efficacy 15.2.3.3 Safety 15.2.3.4 Clinical Study Details 15.2.4 Fluad Pediatric 15.2.4.1 Overview 15.2.4.2 Efficacy 15.2.4.3 Safety 15.2.4.4 Clinical Study Details 15.2.5 Flublok 15.2.5.1 Overview 15.3 Product Profiles Of Marketed Products 15.3.1 Fluarix 15.3.2 Vaxigrip 15.3.3 Influvac 15.3.4 Fluvax 15.3.5 Agrippal 16 Seasonal Influenza Vaccine Market In Asia-pacific – Competitive Landscape 16.1.1 Sanofi Pasteur 16.1.2 Glaxosmithkline Biologicals 16.1.3 Abbott Laboratories (solvay Pharmaceuticals) 16.1.4 Csl Biotherapies 16.1.5 Novartis Vaccines 16.1.6 Crucell N.v. (berna Biotech) 17 Seasonal Influenza Vaccine Market In Asia-pacific – Strategic Consolidations 17.1 Overview 17.2 Major Merger And Acquisition Deals, 2007–2012 17.2.1 Astrazeneca Acquires Medimmune Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 9. 17.2.2 Sanofi-aventis (now Sanofi) Acquires Acambis 17.2.3 Mymetics Acquires Virosome Biologicals 17.2.4 Simcere Pharmaceutical Acquires A Majority Stake In Jiangsu Yanshen Biological Technology Stock 17.2.5 Novartis Completes Acquisition Of 85% Stake In Zhejiang Tianyuan 17.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals 17.2.7 Nutri Pharma Acquires A Majority Stake In Bionor Immuno 17.2.8 Johnson & Johnson Acquires Crucell 17.2.9 Glaxosmithkline To Acquire Remaining Interest In Shenzhen Gsk-neptunus Biologicals 17.3 M&a Deals By Geography 17.4 Major Licensing Agreements, 2007–2012 17.4.1 Crucell Enters Into License Agreement With Adimmune Corporation 17.4.2 Medimmune Enters Into Licensing Agreement With Sanofi Pasteur 17.4.3 Vivalis Enters Into Licensing Agreement With Glaxosmithkline 17.4.4 Vivalis Enters Into Licensing Agreement With Nobilon International 17.4.5 Medimmune Enters Into Licensing Agreement With Glaxosmithkline 17.4.6 Hemispherx Biopharma Enters Into Licensing Agreement With Biken 17.4.7 Medimmune Enters Into Licensing Agreement With Biken 17.4.8 Medimmune Enters Into Licensing Agreement With Omninvest 17.4.9 Opko Health Enters Into Licensing Agreement With Academia Sinica 17.4.10 Altravax Enters Into Licensing Agreement With Maxygen 17.4.11 Protein Sciences Expands Its Licensing Agreement With Umn Pharma For Flublok And Panblok 17.4.12 Nasvax Extends Its Research Agreement With Novartis 17.4.13 Ibio Enters Into Licensing Agreement With G-con 17.5 Licensing Deals By Geography 18 Seasonal Influenza Vaccine Market In Asia-pacific – Appendix 18.1 Market Definitions 18.2 Abbreviations 18.3 Bibliography 18.4 Research Methodology 18.4.1 Coverage 18.4.2 Secondary Research 18.4.3 Primary Research 18.5 Therapeutic Landscape 18.5.1.1 Epidemiology-based Forecasting 18.5.2 Market Size By Geography 18.6 Geographical Landscape 18.7 Pipeline Analysis 18.8 Competitive Landscape 18.8.1 Expert Panel Validation 18.9 Contact Us 18.10 Disclaimer Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity
  • 10. ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity